Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).

Klinghammer K, Gauler T, Dietz A, Grünwald V, Stöhlmacher J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Große-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U.

Eur J Cancer. 2019 Oct 13;122:53-60. doi: 10.1016/j.ejca.2019.08.018. [Epub ahead of print]

PMID:
31618704
2.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Michielin O, van Akkooi A, Ascierto P, Dummer R, Keilholz U; ESMO Guidelines Committee.

Ann Oncol. 2019 Sep 30. pii: mdz411. doi: 10.1093/annonc/mdz411. [Epub ahead of print] No abstract available.

PMID:
31566661
3.

Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature.

Liebs S, Nonnenmacher A, Klauschen F, Keilholz U, Vecchione L.

ESMO Open. 2019 Aug 16;4(4):e000528. doi: 10.1136/esmoopen-2019-000528. eCollection 2019. Review.

4.

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.

Guigay J, Tahara M, Licitra L, Keilholz U, Friesland S, Witzler P, Mesía R.

Front Oncol. 2019 Aug 21;9:668. doi: 10.3389/fonc.2019.00668. eCollection 2019. Review.

5.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T.

Oral Oncol. 2019 Oct;97:82-91. doi: 10.1016/j.oraloncology.2019.08.004. Epub 2019 Aug 23.

PMID:
31450171
6.

VIST - a Variant-Information Search Tool for precision oncology.

Ševa J, Wiegandt DL, Götze J, Lamping M, Rieke D, Schäfer R, Jähnichen P, Kittner M, Pallarz S, Starlinger J, Keilholz U, Leser U.

BMC Bioinformatics. 2019 Aug 16;20(1):429. doi: 10.1186/s12859-019-2958-3.

7.

Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas.

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, Von Der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I.

Oncoimmunology. 2019 May 25;8(8):1614858. doi: 10.1080/2162402X.2019.1614858. eCollection 2019.

PMID:
31413922
8.

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.

Ann Oncol. 2019 May 31. pii: mdz176. doi: 10.1093/annonc/mdz176. [Epub ahead of print]

PMID:
31150059
9.

Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.

Liebs S, Keilholz U, Kehler I, Schweiger C, Haybäck J, Nonnenmacher A.

Cancer Med. 2019 Jul;8(8):3761-3769. doi: 10.1002/cam4.2219. Epub 2019 May 27.

10.

Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures.

Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA.

PLoS Genet. 2019 Mar 29;15(3):e1008076. doi: 10.1371/journal.pgen.1008076. eCollection 2019 Mar. Erratum in: PLoS Genet. 2019 May 29;15(5):e1008183.

11.

Somatic genome alterations in relation to age in lung adenocarcinoma.

Meucci S, Keilholz U, Heim D, Klauschen F, Cacciatore S.

Int J Cancer. 2019 Oct 15;145(8):2091-2099. doi: 10.1002/ijc.32265. Epub 2019 Mar 28.

PMID:
30859574
12.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

13.

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.

Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL.

J Immunother Cancer. 2019 Jan 16;7(1):12. doi: 10.1186/s40425-018-0459-y.

14.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

15.

Variant information systems for precision oncology.

Starlinger J, Pallarz S, Ševa J, Rieke D, Sers C, Keilholz U, Leser U.

BMC Med Inform Decis Mak. 2018 Nov 21;18(1):107. doi: 10.1186/s12911-018-0665-z.

16.

Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.

Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kölbl O, Hautmann MG, Strutz J, Schreiber F, Bockmühl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehülsing M, Schroeder U, Wollenberg B, Sittel C, Münter M, Lenarz T, Klussmann JP, Guntinas-Lichius O, Rudack C, Eich HT, Foerg T, Preyer S, Westhofen M, Welkoborsky HJ, Esser D, Thurnher D, Remmert S, Sudhoff H, Görner M, Bünzel J, Budach V, Held S, Knödler M, Lordick F, Wiegand S, Vogel K, Boehm A, Flentje M, Keilholz U.

Ann Oncol. 2018 Oct 1;29(10):2105-2114. doi: 10.1093/annonc/mdy332.

PMID:
30412221
17.

Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes.

Verver D, van Klaveren D, Franke V, van Akkooi ACJ, Rutkowski P, Keilholz U, Eggermont AMM, Nijsten T, Grünhagen DJ, Verhoef C.

Br J Surg. 2019 Feb;106(3):217-225. doi: 10.1002/bjs.10995. Epub 2018 Oct 11.

18.

Somatic genome alterations in relation to age in lung squamous cell carcinoma.

Meucci S, Keilholz U, Heim D, Klauschen F, Cacciatore S.

Oncotarget. 2018 Aug 14;9(63):32161-32172. doi: 10.18632/oncotarget.25848. eCollection 2018 Aug 14.

19.

Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.

Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ.

Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13.

PMID:
29660597
20.
21.

From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.

Gambara G, Gaebler M, Keilholz U, Regenbrecht CRA, Silvestri A.

Front Pharmacol. 2018 Feb 14;9:77. doi: 10.3389/fphar.2018.00077. eCollection 2018. Review.

22.

Social network, autonomy, and adherence correlates of future time perspective in patients with head and neck cancer.

Baldensperger L, Wiedemann AU, Wessel L, Keilholz U, Knoll N.

Psychooncology. 2018 Jun;27(6):1545-1552. doi: 10.1002/pon.4690. Epub 2018 Mar 24.

PMID:
29490119
23.

Should cT2 esophageal cancer get neoadjuvant treatment before surgery?

Thuss-Patience P, Vecchione L, Keilholz U.

J Thorac Dis. 2017 Sep;9(9):2819-2823. doi: 10.21037/jtd.2017.08.143. No abstract available.

24.

Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells.

Regan JL, Schumacher D, Staudte S, Steffen A, Haybaeck J, Keilholz U, Schweiger C, Golob-Schwarzl N, Mumberg D, Henderson D, Lehrach H, Regenbrecht CRA, Schäfer R, Lange M.

Cell Rep. 2017 Dec 5;21(10):2813-2828. doi: 10.1016/j.celrep.2017.11.025.

25.

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Lodrini M, Sprüssel A, Astrahantseff K, Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A, Deubzer HE.

Oncotarget. 2017 Jul 7;8(49):85234-85251. doi: 10.18632/oncotarget.19076. eCollection 2017 Oct 17.

26.

Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.

Liu Y, Meucci S, Sheng L, Keilholz U.

Oncotarget. 2017 May 26;8(44):77928-77941. doi: 10.18632/oncotarget.18272. eCollection 2017 Sep 29.

27.

Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.

Klinghammer K, Otto R, Raguse JD, Albers AE, Tinhofer I, Fichtner I, Leser U, Keilholz U, Hoffmann J.

Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21.

28.

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.

Keilholz U, Rohde L, Mehlitz P, Knoedler M, Schmittel A, Kümmerlen V, Klinghammer K, Treasure P, Lassus M, Steventon G, Machacek M, Utku N.

Eur J Cancer. 2017 Jul;80:14-25. doi: 10.1016/j.ejca.2017.03.032. Epub 2017 May 19.

PMID:
28531881
29.

p16, HPV, and Cetuximab: What Is the Evidence?

Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB.

Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433. Epub 2017 May 18. Review.

30.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

31.

Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients.

Liu Y, Cheng G, Qian J, Ju H, Zhu Y, Stefano M, Keilholz U, Li D.

Oncotarget. 2017 Jun 13;8(24):38841-38849. doi: 10.18632/oncotarget.16406.

32.

[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].

Miller K, Bergmann L, Doehn C, Gschwend J, Keilholz U.

Aktuelle Urol. 2017 Feb;48(1):72-78. doi: 10.1055/s-0042-117572. Epub 2017 Apr 12. Review. German.

PMID:
28403496
33.

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML.

Nat Commun. 2017 Feb 10;8:14262. doi: 10.1038/ncomms14262.

34.

Targeted Therapy of Head and Neck Cancer.

Rieke DT, Klinghammer K, Keilholz U.

Oncol Res Treat. 2016;39(12):780-786. Epub 2016 Nov 22. Review.

PMID:
27889751
35.

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.

Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A, Vysotskaia V, Wiggin M, Heirich K, Hanft V, Keilholz U, Tinhofer I, Norton JA, Lee M, Sollier-Christen E, Jeffrey SS.

Oncotarget. 2016 Dec 20;7(51):85349-85364. doi: 10.18632/oncotarget.13350.

36.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

37.

Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.

Rieke DT, Keilholz U.

Recent Results Cancer Res. 2017;206:149-160. Review.

PMID:
27699536
38.

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.

Rieke DT, Ochsenreither S, Klinghammer K, Seiwert TY, Klauschen F, Tinhofer I, Keilholz U.

Oncotarget. 2016 Nov 15;7(46):75379-75393. doi: 10.18632/oncotarget.12211.

39.

appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma).

Dummer R, Keilholz U; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v136-v137. No abstract available.

PMID:
27664250
40.

Mutational load and mutational patterns in relation to age in head and neck cancer.

Meucci S, Keilholz U, Tinhofer I, Ebner OA.

Oncotarget. 2016 Oct 25;7(43):69188-69199. doi: 10.18632/oncotarget.11312.

41.

The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer.

Tinhofer I, Budach V, Jöhrens K, Keilholz U.

Cancers Head Neck. 2016 Aug 10;1:8. doi: 10.1186/s41199-016-0009-6. eCollection 2016. Review.

42.

Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer.

Licitra L, Keilholz U, Tahara M, Lin JC, Chomette P, Ceruse P, Harrington K, Mesia R.

Oral Oncol. 2016 Aug;59:73-79. doi: 10.1016/j.oraloncology.2016.06.002. Review.

43.

The Interdisciplinary Management of Brain Metastases.

Schmieder K, Keilholz U, Combs S.

Dtsch Arztebl Int. 2016 Jun 17;113(24):415-21. doi: 10.3238/arztebl.2016.0415. Review.

44.

Prevalence and associated survival of high-risk HPV-related adenoid cystic carcinoma of the salivary glands.

Qian X, Kaufmann AM, Chen C, Tzamalis G, Hofmann VM, Keilholz U, Hummel M, Albers AE.

Int J Oncol. 2016 Aug;49(2):803-11. doi: 10.3892/ijo.2016.3563. Epub 2016 Jun 3.

PMID:
27279281
45.

Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives.

Seifert G, Budach V, Keilholz U, Wust P, Eggert A, Ghadjar P.

Radiat Oncol. 2016 Apr 30;11:65. doi: 10.1186/s13014-016-0639-1. Review.

46.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.

Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB; LUX-H&N 1 investigators.

Ann Oncol. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. Epub 2016 Apr 15.

47.

Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview.

Frick VO, Rubie C, Keilholz U, Ghadjar P.

World J Gastroenterol. 2016 Jan 14;22(2):833-41. doi: 10.3748/wjg.v22.i2.833. Review.

48.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

PMID:
26790144
49.

Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients.

Dielmann A, Letsch A, Nonnenmacher A, Miller K, Keilholz U, Busse A.

Cancer Immunol Immunother. 2016 Feb;65(2):181-92. doi: 10.1007/s00262-015-1786-1. Epub 2016 Jan 11.

PMID:
26753694
50.

Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck.

Licitra L, Mesía R, Keilholz U.

Oral Oncol. 2016 Jan;52:18-23. doi: 10.1016/j.oraloncology.2015.10.020. Epub 2015 Nov 11. Review.

PMID:
26578389

Supplemental Content

Loading ...
Support Center